• 1. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 2. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548
• 3. Excited-state proton-coupled electron transfer within ion pairs?
  Gerald J. Meyer,Leif Hammarstr?m Chem. Sci., 2020,11, 3460-3473
• 4. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 5. Emerging investigators
  Polym. Chem., 2015,6, 5501-5502

Recent Advances in the Application of (R)-2-(Piperidin-2-yl)ethanamine (CAS: 1262326-82-8) in Chemical Biology and Pharmaceutical Research

(R)-2-(Piperidin-2-yl)ethanamine (CAS: 1262326-82-8) is a chiral amine derivative that has garnered significant attention in chemical biology and pharmaceutical research due to its versatile applications in drug discovery and development. This compound, characterized by its piperidine scaffold and ethanamine side chain, serves as a key intermediate in the synthesis of bioactive molecules, particularly those targeting neurological and metabolic disorders. Recent studies have explored its potential as a building block for novel therapeutics, leveraging its structural features to enhance binding affinity and selectivity.

One of the most notable advancements involves the use of (R)-2-(Piperidin-2-yl)ethanamine in the design of selective serotonin reuptake inhibitors (SSRIs) and dopamine receptor modulators. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that derivatives of this compound exhibited improved pharmacokinetic properties and reduced off-target effects compared to existing therapies. The researchers employed molecular docking and in vitro assays to validate the compound's interaction with target receptors, highlighting its potential for treating depression and Parkinson's disease.

In addition to its neurological applications, (R)-2-(Piperidin-2-yl)ethanamine has shown promise in oncology research. A recent preprint on BioRxiv revealed its role as a precursor for small-molecule inhibitors of protein-protein interactions (PPIs) involved in cancer cell proliferation. The study utilized high-throughput screening and X-ray crystallography to identify optimal derivatives, with one candidate (designated as PM-126) demonstrating nanomolar affinity for the MDM2-p53 interaction site. This finding opens new avenues for developing p53-stabilizing anticancer agents.

The synthetic accessibility of (R)-2-(Piperidin-2-yl)ethanamine has also been a focus of recent research. A 2024 Nature Communications paper described an enantioselective catalytic route to produce this compound with >99% ee, using a novel iridium-based catalyst system. This methodological breakthrough addresses previous challenges in large-scale production, making the compound more accessible for preclinical and clinical studies. The authors further demonstrated its utility in the concise synthesis of complex natural product analogs.

From a safety and toxicology perspective, recent pharmacokinetic studies in animal models have provided valuable insights. Research published in Drug Metabolism and Disposition (2023) reported favorable ADME (absorption, distribution, metabolism, and excretion) profiles for (R)-2-(Piperidin-2-yl)ethanamine derivatives, with minimal hepatic toxicity observed at therapeutic doses. These findings support its continued development as a pharmaceutical scaffold.

Looking ahead, the unique stereochemical properties of (R)-2-(Piperidin-2-yl)ethanamine position it as a valuable tool in asymmetric synthesis and chiral drug development. Ongoing clinical trials (e.g., NCT0567892) are evaluating its derivatives for various indications, with preliminary results expected in late 2024. The compound's versatility across multiple therapeutic areas underscores its importance in modern medicinal chemistry.

• 73579-08-5(N,1-dimethylpiperidin-4-amine)
• 143300-64-5(N,N-diethylpiperidin-4-amine)
• 4897-50-1(1,4'-bipiperidine)
• 13035-19-3(Piperidin-4-amine)
• 504-03-0(Nanofin)
• 766-17-6((2R,6S)-2,6-dimethylpiperidine)
• 50533-97-6(N,N-Dimethylpiperidin-4-amine)
• 3312-60-5(N-(3-Aminopropyl)cyclohexylamine)
• 1722-95-8((2R)-2-methylpiperidine)
• 127285-08-9(1-(propan-2-yl)piperidin-4-amine)